[{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Pramlintide Insulin","moa":"Amylin receptor\/Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ADO09","moa":"GLP-1\/Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ADO09","moa":"GLP-1\/Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Adocia"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Eli Lilly"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Eli Lilly"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Eli Lilly"},{"orgOrder":0,"company":"Adocia","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Eli Lilly"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Virchow Group","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Adocia \/ Adocia","highestDevelopmentStatusID":"7","companyTruncated":"Adocia \/ Adocia"},{"orgOrder":0,"company":"Adocia","sponsor":"Virchow Group","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Virchow Group","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Virchow Group"},{"orgOrder":0,"company":"Adocia","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Biochaperone Insulin Lispro","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Eli Lilly"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"M1 Pram P037","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Michael Tsoukas","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bc Lispram","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Michael Tsoukas","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Michael Tsoukas"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Adocia

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Insulin Lispro, a peptide targeting the insulin receptor, shows promise in treating Type 1 Diabetes.

                          Product Name : BioChaperone Lispro

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          October 15, 2025

                          Lead Product(s) : Insulin Lispro

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary t...

                          Product Name : BioChaperone Lispro

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 14, 2021

                          Lead Product(s) : Insulin Lispro

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Recipient : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Bc Lispram is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 22, 2021

                          Lead Product(s) : Bc Lispram

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Michael Tsoukas

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.

                          Product Name : BC LisPram

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 29, 2021

                          Lead Product(s) : Insulin Lispro,Pramlintide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.

                          Product Name : PramExe

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 26, 2021

                          Lead Product(s) : Pramlintide,Exenatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : M1 Pram P037 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 25, 2021

                          Lead Product(s) : M1 Pram P037

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.

                          Product Name : BC LisPram

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          March 10, 2021

                          Lead Product(s) : Insulin Lispro

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank